Loading

Please wait...

Prolia

Generic Name: denosumab (Prolia) (den OH sue mab)
Brand Names: Prolia
Prolia (denosumab) is used to treat osteoporosis in postmenopausal women who have high risk of bone fracture. Includes Prolia side effects, interactions and indications.
  • Prescription Settings
  • X
  • Local Pharmacy Pickup available at . Pick up your medication at any of our participating pharmacies.
  • Mail Order Home Delivery available at , the easiest way to receive your medications.
  • Learn more

Prolia Coupons & Prices

Set your location
for drug prices near you

Enter your zip code

Please wait while the prices are loaded...
Click here to try again.

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Prolia (denosumab) is a monoclonal antibody. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage. The Prolia brand of denosumab is used to treat osteoporosis in postmenopausal women who have high risk of bone fracture. Prolia is used to increase bone mass in men with osteoporosis with a high risk of bone fracture, and in women and men with a high risk of bone fracture caused by receiving treatments for certain types of cancer. Learn more

Pickup / Home Delivery

USARx offers multiple ways to purchase this medication. Choose the Best option for you!

  • Guaranteed Price
    Local Pharmacy Pickup

    Pay this amount and pick up your prescription at ANY Retail pharmacy of your choice! Walgreens, CVS, Walmart, etc.

  • 30-day supply
    90-day supply
    Mail Order Home Delivery

    The easiest way to receive your medications.

Prolia Side Effects

Note: This document contains side effect information about denosumab. Some of the dosage forms listed on this page may not apply to the brand name Prolia.

For the Consumer

Applies to denosumab: subcutaneous solution

Along with its needed effects, denosumab (the active ingredient contained in Prolia) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking denosumab:

More common

  • Back pain
  • blistering, crusting, irritation, itching, or reddening of the skin
  • bloody or cloudy urine
  • cracked, dry, or scaly skin
  • difficult, burning, or painful urination
  • frequent urge to urinate
  • muscle or bone pain
  • pain in the arms or legs
  • rash
  • skin rash, encrusted, scaly, and oozing
  • swelling

Less common

  • Arm or jaw pain
  • bloating or swelling of the face, arms, hands, lower legs, or feet
  • body aches or pain
  • chest pain or discomfort
  • chest tightness or heaviness
  • chills
  • confusion
  • congestion
  • cough
  • difficulty with breathing
  • difficulty with moving
  • dryness or soreness of the throat
  • ear congestion
  • fast or irregular heartbeat
  • fever
  • headache
  • hoarseness
  • joint pain
  • loss of voice
  • muscle cramps in the hands, arms, feet, legs, or face
  • muscle stiffness
  • numbness and tingling around the mouth, fingertips, hands, or feet
  • pain in the lower back, bottom, upper leg, or hips
  • painful blisters on the trunk of the body
  • pale skin
  • rapid weight gain
  • runny or stuffy nose
  • seizures
  • sneezing
  • stomach cramps
  • swollen joints
  • tender, swollen glands in the neck
  • tremor
  • trouble swallowing
  • troubled breathing with exertion
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • unusual weight gain or loss
  • voice changes

Rare

  • Blood in the stool
  • change in bowel habits
  • clear or bloody discharge from the nipple
  • constipation
  • darkened urine
  • difficulty with eating
  • dimpling of the breast skin
  • indigestion
  • inverted nipple
  • itching, pain, redness, swelling, tenderness, or warmth on the skin
  • loss of appetite
  • lower back or side pain
  • lump in the breast or under the arm
  • lump or swelling in the abdomen or stomach
  • nausea
  • pains in the stomach, side, or abdomen, possibly radiating to the back
  • persistent crusting or scaling of the nipple
  • raised, firm, and bright red patches of the skin on the arm or leg
  • redness or swelling of the breast
  • sore on the skin of the breast that does not heal
  • stomach discomfort
  • unexplained weight loss
  • vomiting
  • yellow eyes or skin

Incidence not known

  • Heavy feeling in the jaw
  • loose teeth
  • pain, swelling, or numbness in the mouth or jaw

Some side effects of denosumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

  • Dizziness or lightheadedness
  • excess air or gas in the stomach or bowels
  • feeling of constant movement of self or surroundings
  • feeling of fullness
  • heartburn
  • lack or loss of strength
  • passing gas
  • redness, pain, itching, burning, swelling, or a lump under your skin where the shot was given
  • sensation of spinning
  • trouble sleeping
  • upper abdominal or stomach pain

For Healthcare Professionals

Applies to denosumab: subcutaneous solution

Cardiovascular

Common (1% to 10%): Angina pectoris, atrial fibrillation

Hypersensitivity

Postmarketing reports: Anaphylaxis, rash, urticaria, facial swelling, erythema

Respiratory

Very common (10% or more): Dyspnea (21%), cough (15%)

Common (1% to 10%): Upper respiratory tract infection, pneumonia, pharyngitis, nasopharyngitis

General

The most commonly reported side effects were asthenia, fatigue, back pain, hypophosphatemia, hypocalcemia, and nausea.

Musculoskeletal

Very common (10% or more): Back pain (35%), arthralgia (14%), pain in extremity (12%)

Common (1% to 10%): Musculoskeletal pain, bone pain, myalgia, spinal osteoarthritis

Rare (less than 0.1%): Atypical femoral fractures

Frequency not reported: Osteonecrosis of the jaw, atypical subtrochanteric and diaphysealfemoral fractures

Postmarketing reports: Musculoskeletal pain including severe cases, multiple vertebral fractures following discontinuation of this drug

Metabolic

Very common (10% or more): Hypophosphatemia (32%), hypocalcemia (including fatal cases) (18%)

Common (1% to 10%): Hypercholesterolemia

Postmarketing reports: Severe symptomatic hypocalcemia, severe symptomatic hypercalcemia following treatment discontinuation

Dermatologic

Very common (10% or more): Dermatitis (11%), eczema (11%), rash (11%)

Common (1% to 10%): Pruritus, hyperhidrosis

Uncommon (0.1% to 1%): Cellulitis

Postmarketing reports: Cutaneous and mucosal lichenoid drug eruptions (e.g., lichen planus-like reactions), alopecia

Gastrointestinal

Very common (10% or more): Nausea (31%), diarrhea (20%)

Common (1% to 10%): Upper abdominal pain, flatulence, gastroesophageal reflux disease, constipation, abdominal discomfort, tooth extraction

Uncommon (0.1% to 1%): Pancreatitis, diverticulitis

Nervous system

Very common (10% or more): Headache (13%)

Common (1% to 10%): Vertigo, sciatica

Genitourinary

Common (1% to 10%): Urinary tract infections, cystitis

Hematologic

Common (1% to 10%): Anemia

Endocrine

Postmarketing reports: Marked elevation in serum PTH in patients with severe renal impairment (CrCl less than 30 mL/min) or receiving dialysis

Immunologic

Receptor activator of nuclear factor kappa-B ligand (RANKL) is expressed on activated T and B lymphocytes and in lymph nodes; therefore, a RANKL inhibitor such as this drug may increase the risk of infection. A study of postmenopausal women with osteoporosis (n=7808), has shown a higher incidence of nonfatal serious infections in those receiving this drug compared with placebo (4% vs 3.3%). Hospitalizations due to serious infections in the abdomen (0.9% vs 0.7%), urinary tract (0.7% vs. 0.5%), ear (0.1% vs. 0%) and skin, including erysipelas and cellulitis (0.4% vs. less than 0.1%) were reported. Endocarditis was reported in 3 patients receiving this drug and no placebo patients. The incidence of infections resulting in death was 0.2% in both groups and the incidence of opportunistic infections was the same in both groups.

Common (1% to 10%): Herpes zoster, serious infections (nonfatal cases)

Uncommon (0.1% to 1%): Serious Infections (fatal cases)

Ocular

Common (1% to 10%): Cataracts

Oncologic

New malignancies were reported in 4.8% of patients receiving this drug (placebo=4.3%); new malignancies included breast (0.9%), reproductive system (0.5%), and gastrointestinal system (0.9%). A causal relationship to drug exposure has not been established.

Common (1% to 10%): New malignancies

Uncommon (0.1% to 1%): Basal cell carcinoma

Other

Very common (10% or more): Asthenia (45%), fatigue (45%)

Common (1% to 10%): Peripheral edema

Uncommon (0.1% to 1%): Ear infection

Psychiatric

Common (1% to 10%): Insomnia

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.

Source: Drugs.com Prolia (www.drugs.com/prolia.html).